RFK Jr.'s peptide policy explained: HHS lets pharmacies compound BPC-157 and 5 more (Oct 2026)

On 28 October 2026, the US Department of Health and Human Services (HHS) filed a notice with the Federal Register saying it will not take enforcement action against pharmacies that compound six peptides: BPC-157, TB-500, Epitalon, Semax, KPV and MOTS-c. The notice is signed by Health Secretary Robert F. Kennedy Jr. and is scheduled for publication on 30 October 2026. That is why searches for "RFK peptides" jumped this week. Here is what the policy actually does, what it does not do, and what it means for research peptides.

What HHS announced

The Federal Register notice is a "notice of availability" for an HHS policy titled Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. It says HHS "does not intend to take enforcement action" against a state-licensed pharmacy, federal facility or licensed physician that compounds with one of the listed peptides, provided the conditions in the policy are met.

The policy is temporary by design. It applies while FDA builds the list of bulk drug substances that 503A pharmacies may use, through formal rulemaking. The notice says future rulemaking "may propose adding some or all of these peptides" to that list, and that HHS may revisit the policy if a safety signal or product quality issue arises. The notice also states that it is not binding and creates no legal rights.

The six peptides and the product forms allowed

Appendix B of the HHS policy names each peptide's chemical form and limits which kinds of compounded products are covered. Anything outside these forms, and any other peptide, falls outside the policy.

Popular peptides that are not on this list, including GHK-Cu, Selank and DSIP, are not covered. Blends are not covered either: the policy requires a single listed active ingredient per product, so a BPC-157 and TB-500 combination does not qualify.

The conditions pharmacies must meet

• Registered source: the original manufacturer of the peptide must be registered with FDA under section 510 and work to current good manufacturing practice. A repacker or reseller's registration alone is not enough.
• Certificate of analysis: each lot needs a COA that lists the manufacturing site, with testing for identity, purity, potency, impurities, residual solvents, elemental impurities, microbial contamination and bacterial endotoxins. Our guide to verifying a peptide COA explains what these tests mean.
• Patient-specific prescriptions: the normal 503A rules still apply, so this is not permission for general manufacturing or retail sale.
• Labeling and reporting: products must carry the statement "This is a compounded drug product. Not for resale.", and serious adverse events and quality problems must be reported to FDA's MedWatch program and to state authorities.
• Oral products: compounders must document that the oral formulation is adequately absorbed. HHS itself notes this is "inherently difficult and complex" for peptides.

How this connects to the July 2026 FDA vote

In July 2026, FDA's Pharmacy Compounding Advisory Committee voted in favor of these peptides for the 503A bulks list, while FDA's drug center (CDER) had recommended against listing them. We covered that meeting in the FDA peptide vote. An advisory vote is not binding, and FDA had not issued a rule. The new HHS policy acts on the committee's view in the meantime, through enforcement discretion rather than a rule change.

What did not change

• No approvals. The notice states plainly that compounded drugs are not FDA-approved, so FDA does not review their safety, effectiveness or quality.
• No change for "research use only" sellers. The policy covers licensed compounding only. HHS presents it as a controlled alternative to "research-use-only peptides supplied by foreign manufacturers that pose a safety risk to US patients". FDA warning letters to online sellers, which we track in our warning letters tracker, are a separate matter.
• No change outside the US. In the UK, EU, Canada and Australia the rules in our legal guide still apply. UK readers can see are peptides legal in the UK?
• No change in sport. BPC-157 remains on the WADA Prohibited List.

Reaction

The Partnership for Safe Medicines said the decision "leaves Americans in a grey area" and pointed to FDA scientists' concerns about the evidence. It has filed a citizen petition asking FDA to set aside the July vote. Health experts quoted by the BBC warned about the lack of human clinical trials and unknown long-term effects. HHS describes the policy as a more controlled route than the gray market.

What happens next

• Publication in the Federal Register on 30 October 2026, followed by a two-week comment period on regulations.gov (docket HHS-OASH-2026-0496).
• FDA rulemaking on the 503A bulks list, which will decide each peptide's long-term status.
• Possible changes if HHS sees a safety signal or quality problem, which the notice explicitly allows for.

For the research background on each compound, browse the peptide library. This page summarises the notice and published analysis as of 29 October 2026 and is not legal or medical advice.

Frequently asked questions

Sources

1. Federal Register public inspection 2026-22192: Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (filed 28 October 2026)
2. HHS: 503A peptide enforcement discretion policy, Appendix B
3. Frier Levitt: HHS peptide compounding enforcement discretion policy
4. Partnership for Safe Medicines: statement on the 503A peptide enforcement policy (28 October 2026)
5. BBC via Yahoo News: US Health Secretary RFK Jr to expand access to unapproved peptides (29 October 2026)